NCCN guidelines have approved atezolizumab (ICI targeting PD-L1), nivolumab (ICI targeting PD-1), pembrolizumab (ICI targeting PD-1), and ipilimumab (ICI targeting CTLA-4) for treating NSCLC as they significantly prolong survival in some patients [5]. Here, CD274 is linked to non-small cell lung carcinoma.